ARQ 087

Drug Profile

ARQ 087

Alternative Names: ARQ-087

Latest Information Update: 09 Mar 2017

Price : $50

At a glance

  • Originator ArQule
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fibroblast growth factor receptor antagonists; Phosphotransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cholangiocarcinoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma
  • Phase I Solid tumours

Most Recent Events

  • 08 Mar 2017 ArQule completes enrolment in its phase I/II trial for Cholangiocarcinoma in USA and Italy (NCT01752920)
  • 30 Jun 2016 Preliminary efficacy and adverse events data from a phase I/II trial in Cholangiocarcinoma (Intrahepatic) presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
  • 23 Jun 2016 ARQ 087 receives Orphan Drug status for Cholangiocarcinoma in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top